Vivoryon Therapeutics N.v. · EURONEXT:VVY
Vivoryon Therapeutics — Shareholder Meeting (September 2026)
23 slides from Vivoryon Therapeutics's shareholder meeting presentation, Sep 29, 2026
Slide 1: Annual General Meeting 2026
Annual General Meeting 2026 September 29, 2026 Amsterdam, The Netherlands Vivoryon Therapeutics N.V.
Slide 2: Agenda
Report of the Board for the financial year 2025 (discussion item) Remuneration report for the financial year 2025 (advisory voting item) Annual accounts for the financial year 2025 (voting item) Reservation and dividend policy (discussion item) Release from liability of the Company’s executive direc
Slide 3: Report of the Board: Financial year 2025 and post period
Report of the Board Financial year 2025 and post period 3
Slide 4: Important notice and disclaimer
Important notice and disclaimer This document has been prepared by Vivoryon Therapeutics N.V. (the “Company” or “We”) strictly only for discussion purposes. This document does not constitute or form part of any offer or invitation to sell or issue, any offer or inducement or invitation or commitment
Slide 5: Developing new therapies that aim to preserve kidney function
Developing new therapies that aim to preserve kidney function and prevent progression to kidney failure 5
Slide 6: Developing new therapies to preserve kidney function and prevent kidney failure
Developing new therapies with the aim of preserving kidney function and preventing progression to kidney failure Significant unmet need in Compelling data with lead Attractive opportunity with diabetic kidney disease (DKD) program varoglutamstat defined value-creation steps ~1.5M patients in U.S. an
Slide 7: Varoglutamstat has potential to significantly improve outcomes by preserving kidney function
Varoglutamstat has potential to significantly improve patient outcomes by preserving kidney function Current SoC Varoglutamstat Shown to improve kidney function • Data from 2 independent Phase 2 studies • Prominent effect in participants with diabetes Kidney function Stabilizes or continues to decli
Slide 8: 2025 & recent achievements
2025 & recent achievements: Continued to build robust body of evidence for varoglutamstat in kidney disease and drive strategic priorities Strong clinical & Corporate Advancing scientific evidence updates strategic priorities ◆ Compelling kidney function data and ◆ U.S. composition of matter patent
Slide 9: Varoglutamstat reduces pro-inflammatory signaling by destabilizing key inflammatory molecules
Varoglutamstat reduces pro-inflammatory signaling by destabilizing key inflammatory molecules Varoglutamstat targets pro-inflammatory and pro-fibrotic pathways in kidney disease ACTIVED / SILENCED INFLAMMATORY Inflammatory pyroglutamated- protein version (pE) Impaired Varoglutamstat kidney treated Q
Slide 10: Compelling beneficial effect on kidney function versus placebo
Compelling beneficial effect on kidney function in subjects treated with varoglutamstat compared to placebo Change in eGFR over time; pooled data from VIVIAD and VIVA-MIND (MMRM); All subjects; 600mg BID varoglutamstat Varoglutamstat Clear and consistent separation of curves after 24 weeks baseline
Slide 11: Substantial treatment effect in patients with high risk of progressive kidney disease
Varoglutamstat has a substantial treatment effect in patients with high risk of progressive kidney disease Results for all participants, those with/without hypertension (HTN) and/or diabetes, and those with/without diabetes Treatment effect (annualized rate of change in eGFR / eGFR slope) 600 mg BID
Slide 12: Targeting inflammation and fibrosis offers a complementary approach to existing therapies
Targeting inflammation and fibrosis offers a complementary approach to existing therapies by tackling DKD at its roots Varoglutamstat: QPCT/L inhibitor Inflammation/ Inflammation/ Complementary approach Fibrosis Fibrosis Inhibition Inhibition of pro-inflammatory targeting inflammation/fibrosis; of p
Slide 13: Progressing strategic priorities to secure development of varoglutamstat
Progressing strategic priorities to secure development of varoglutamstat Advanced term sheet negotiations for a licensing agreement for varoglutamstat with a pharmaceutical / biotech company Multiple tracks ongoing Specialist kidney investor independently assessing varoglutamstat’s to secure develop
Slide 14: Key financial figures
Key financial figures In €k Six months ended Twelve months ended Twelve months ended Jun 30, 2026 Dec. 31, 2025 Dec. 31, 2024 Revenue 0 0 0 Research & Development expenses (1,659) (4,381) (14,058) General & Administrative expenses (1,732) (4,796) (6,903) Net loss for the period (3,388) (8,853) (20,5
Slide 15: Notification Pursuant to Article 2:108a of the Dutch Civil Code
Notificaton Pursuant to Article 2:108a of the Dutch Civil Code Equity may decrease to or below 50% of share Focus on measures to strengthen Company’s capital liquidity ◆ In accordance with Section 2:108a of the Dutch Civil Code, ◆ Cash utilization reduction the board points out that it has become ap
Slide 16: Vivoryon's approach and expertise positions company for future growth
Vivoryon’s approach and expertise positions company for future growth Strong Poised to Advancing clinical address strategic evidence medical priorities base need ◆ First in class oral QPCT/L ◆ New therapies needed that ◆ Advanced partnership and inhibitor improve or stabilize kidney funding negotiat
Slide 17: Q&A
Qé&A Wvivoryon
Slide 18: Report of the Auditor: KPMG
Report of the Auditor: KPMG Bas Gerling 18
Slide 19: AGM Vivoryon Therapeutics N.V.
AGM Vivoryon Therapeutics N.V. Bas Geerling 29 September 2026
Slide 20: Our audit process
Our audit process Risk Assessment • Fraud Risks: presumed risk of management override of controls; • Going Concern Risk: Material Financial statements Uncertainty identified related to Going • Auditor’s report on financial statements Concern; • Our opinion: unqualified – Page 97 of the • Climate-ris
Slide 21: Our observations around the going concern assumption
Our observations around the going concern assumption Going concern Material uncertainty related to Going Concern. We assessed management’s going concern evaluation by: • Challenging the key assumptions underpinning management’s assessment and funding plans. • Evaluating the budgeting process. • Asse
Slide 22: Thank You!
Thank You!
Slide 23: Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. Halle (Saale) Weinbergweg 22 06120 Halle (Saale), Germany Munich Franz-Josef-Delonge-Str. 5 81249 München, Germany IR@vivoryon.com www.vivoryon.com
Vivoryon Therapeutics — Shareholder Meeting (September 2026) on 6ix